Association of Methamphetamine and Opioid Use With Nonfatal Overdose in Rural Communities
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Importance: Overdoses continue to increase in the US, but the contribution of methamphetamine use is understudied in rural communities. Objective: To estimate the prevalence of methamphetamine use and its correlates among people who use drugs (PWUD) in rural US communities and to determine whether methamphetamine use is associated with increased nonfatal overdoses. Design, Setting, and Participants: From January 2018 through March 2020, the National Rural Opioid Initiative conducted cross-sectional surveys of PWUD in rural communities in 10 states (Illinois, Kentucky, New Hampshire, Massachusetts, North Carolina, Ohio, Oregon, Vermont, West Virginia, and Wisconsin). Participants included rural PWUD who reported any past-30-day injection drug use or noninjection opioid use to get high. A modified chain-referral sampling strategy identified seeds who referred others using drugs. Data analysis was performed from May 2021 to January 2022. Exposures: Use of methamphetamine alone, opioids alone, or both. Main Outcomes and Measures: Unweighted and weighted prevalence of methamphetamine use, any past-180-day nonfatal overdose, and number of lifetime nonfatal overdoses. Results: Among the 3048 participants, 1737 (57%) were male, 2576 (85%) were White, and 225 (7.4%) were American Indian; the mean (SD) age was 36 (10) years. Most participants (1878 of 2970 participants with any opioid or methamphetamine use [63%]) reported co-use of methamphetamine and opioids, followed by opioids alone (702 participants [24%]), and methamphetamine alone (390 participants [13%]). The estimated unweighted prevalence of methamphetamine use was 80% (95% CI, 64%-90%), and the estimated weighted prevalence was 79% (95% CI, 57%-91%). Nonfatal overdose was greatest in people using both methamphetamine and opioids (395 of 2854 participants with nonmissing overdose data [22%]) vs opioids alone (99 participants [14%]) or methamphetamine alone (23 participants [6%]). Co-use of methamphetamine and opioids was associated with greater nonfatal overdose compared with opioid use alone (adjusted odds ratio, 1.45; 95% CI, 1.08-1.94; P = .01) and methamphetamine use alone (adjusted odds ratio, 3.26; 95% CI, 2.06-5.14; P < .001). Those with co-use had a mean (SD) of 2.4 (4.2) (median [IQR], 1 [0-3]) lifetime overdoses compared with 1.7 (3.5) (median [IQR], 0 [0-2]) among those using opioids alone (adjusted rate ratio, 1.20; 95% CI, 1.01-1.43; P = .04), and 1.1 (2.9) (median [IQR], 0 [0-1]) among those using methamphetamine alone (adjusted rate ratio, 1.81; 95% CI, 1.45-2.27; P < .001). Participants with co-use most often reported having tried and failed to access substance use treatment: 827 participants (44%) for both, 117 participants (30%) for methamphetamine alone, and 252 participants (36%) for opioids alone (χ22 = 33.8; P < .001). Only 66 participants (17%) using methamphetamine alone had naloxone. Conclusions and Relevance: These findings suggest that harm reduction and substance use disorder treatment interventions must address both methamphetamine and opioids to decrease overdose in rural communities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis
Ciccarone, D. (2021) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000717 · Cited by 987
Contingency management for the treatment of methamphetamine use disorder: A systematic review
Brown, H. D., & DeFulio, A. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108307 · Cited by 175 · cited 3×
“(%) MA prevalence, % (95% CI) Overall 3048 (100) 80 (64-90) 12 556 (100) 79 (57-91) Illinois 173 (6) 80 (73-86) 425 (3) 78 (68-87) Kentucky 338 (11) 79 (73-82) 1799 (14) 62 (51-72) North Carolina 350 (11) 93 (90-95) 1406 (11) 91 (86-96) New Englanda 589 (19) 34 (31-39) 861 (19) 32 (28-36) Ohio 258 (8) 80 (76-84) 822 (…”
Increases in methamphetamine use among heroin treatment admissions in the United States, 2008–17
Jones, C. M., Underwood, N., & Compton, W. M. (2020) · Addiction · doi:10.1111/add.14812 · Cited by 142 · cited 1×
“Binge drinking in the last 30 d 912 (31) 97 (25) 185 (26) 630 (34) <.”
Oluwoye, O., Kriegel, L., Alcover, K. C., McPherson, S., McDonell, M. G., & Roll, J. M. (2020) · Psychology of Addictive Behaviors · doi:10.1037/adb0000487 · Cited by 61 · cited 1×
“(%) MA prevalence, % (95% CI) Overall 3048 (100) 80 (64-90) 12 556 (100) 79 (57-91) Illinois 173 (6) 80 (73-86) 425 (3) 78 (68-87) Kentucky 338 (11) 79 (73-82) 1799 (14) 62 (51-72) North Carolina 350 (11) 93 (90-95) 1406 (11) 91 (86-96) New Englanda 589 (19) 34 (31-39) 861 (19) 32 (28-36) Ohio 258 (8) 80 (76-84) 822 (…”
Cited by
Tilhou, A. S., Zaborek, J., Baltes, A., Salisbury-Afshar, E., Malicki, J., & Brown, R. (2023) · Harm Reduction Journal · doi:10.1186/s12954-023-00767-0 · Cited by 30
“Rising rates of co-involved stimulant-fentanyl overdose [3, 4], particularly among individuals without known opioid use disorder [5], demonstrate the substantial risk of overdose from unintentional fentanyl use.”
BackgroundSelf-citationIvsins, A., Bonn, M., McNeil, R., Boyd, J., & Kerr, T. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.111275 · Cited by 22
Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder
Brett, J., Knock, E., Korthuis, P. T., Liknaitzky, P., Murnane, K. S., Nicholas, C. R., Patterson, J. C., & Stauffer, C. S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1123424 · Cited by 16
“Polysubstance use is prevalent among people who use methamphetamine (37, 72); those with polysubstance use and greater use severity may stand to benefit most from innovative transdiagnostic treatments.”
BackgroundSelf-citation
Metadata
- Authors
- Korthuis, P. T., Cook, R. R., Foot, C. A., Leichtling, G., Tsui, J. I., Stopka, T. J., Leahy, J., Jenkins, W. D., Baker, R., Chan, B., Crane, H. M., Cooper, H. L., Feinberg, J., Zule, W. A., Go, V. F., Estadt, A. T., Nance, R. M., Smith, G. S., Westergaard, R. P., Van Ham, B., Brown, R., & Young, A. M.
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2022-08-15
- Volume
- 5
- Issue
- 8
- Pages
- e2226544
- ISSN
- 2574-3805 (ISSN-L)
- OpenAlex
- W4292367497
- Cited by
- 102
- References
- 4
- FWCI
- 16.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.